Emgality (galcanezumab-gnlm) — Medica

Initial criteria

• Patient is age ≥ 18 years
• Patient has ≥ 4 migraine headache days per month prior to initiating a migraine-preventive medication

Reauthorization criteria

• If the patient is currently taking Emgality, the patient has had a significant clinical benefit from the medication as determined by the prescriber (e.g., reduction in overall number of migraine days per month or reduction in number of severe migraine days per month)

Approval duration

1 year